Gedeon Richter, Forest tout promising results from antipsychotic Ph3

Investigators are reporting promising preliminary top-line results from a late-stage study of an experimental antipsychotic being studied by Hungary's Gedeon Richter and Forest Laboratories ($FRX). Shares of Gedeon Richter climbed a bit on the news.

Bipolar patients suffering from acute mania reported progress as early as 5 days after beginning treatment with cariprazine (RGH-188). Cariprazine is also being investigated in clinical studies for patients with schizophrenia, bipolar depression, and as an adjunct treatment for major depression.

"As we continue to move forward with the development of this important compound, these positive phase III results further demonstrate the opportunity for cariprazine as a potential new treatment option for patients suffering from bipolar mania" said Marco Taglietti, senior VP of R&D at the Forest Research Institute.

"In the three consecutive positive trials, statistically significant results demonstrated improvement in symptoms compared to placebo, importantly including the low dose range arm," noted Gedeon's Zsolt Szombathelyi.

- here's the press release
- get the story from Bloomberg

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.